NextPlat Q2 2026 Earnings: Gross Margin Reaches 40% as Loss Narrows

NextPlat (NASDAQ: NXPL) reported Q2 2026 revenue of $11.9 million, down about 10% from $13.2 million a year earlier, while diluted EPS improved to -$0.05 from -$0.69. Revenue increased approximately 21% sequentially from $9.9 million in Q1, supported by contracted healthcare services and e-commerce growth. A shift toward higher-margin pharmacy services lifted gross margin to approximately 40% and brought the company close to GAAP operating breakeven.

Core financial results

The year-over-year revenue decline contrasted with a substantial improvement in gross profit. Gross profit increased approximately 63% to $4.7 million even as revenue fell, reflecting a larger contribution from contracted pharmacy services and lower drug acquisition costs.

Operating expenses increased only slightly despite a $0.5 million increase in professional fees. Combined with the higher gross margin, this reduced the GAAP operating loss to $127,000 and the net loss attributable to common stockholders to $144,000.

Business and segment performance

Healthcare results reflected a shift in revenue mix. Contracted pharmacy revenue increased 136% year over year to approximately $2.2 million from $0.9 million and rose about 20% sequentially. The increase included approximately $0.7 million from 340B contracts and $0.6 million from medication fulfillment services secured late in 2025.

Existing 340B contracts accounted for approximately $0.6 million of the increase, while new contracts contributed about $0.1 million. Related prescription volumes grew more than 33% year over year, and NextPlat signed 11 new contracted entities during the first half of 2026.

Total pharmacy prescription revenue nevertheless declined to approximately $5.6 million from $8.2 million a year earlier. NextPlat attributed the decrease primarily to lower payer reimbursement rates and payer mix. Healthcare gross margin rose to approximately 46% from 39% in Q1 2026 and 20% in Q2 2025, helped by contracted medication fulfillment services and lower drug acquisition costs under the Medicare Drug Price Negotiation Program.

E-commerce revenue increased approximately 27% sequentially to $4.1 million from $3.2 million. Growth came from satellite connectivity, IoT and Push-to-Talk hardware, as well as higher-margin airtime services for international government and military customers. E-commerce gross margin reached approximately 27%, compared with 25% in Q1 2026 and 26% a year earlier. Government and military sales exceeded $1.75 million through the first half of 2026.

Profitability and balance sheet

Selling, general and administrative expense increased to $2.4 million from $2.0 million, while salaries, wages and payroll taxes declined to $2.3 million from $2.6 million. Management attributed the overall increase in operating expenses primarily to a $0.5 million rise in professional fees. Excluding that item, the company said operating expenses declined approximately 8% and that it achieved profitability during the quarter, although it did not provide a separately quantified adjusted earnings measure.

NextPlat ended June with $11.9 million in cash and approximately $14.2 million in working capital, compared with $13.7 million in cash at the end of 2025. Receivables increased to $8.2 million from $5.9 million, inventory rose to $4.1 million from $3.4 million, and accounts payable and accrued expenses increased to $10.3 million from $8.3 million over the same six-month period.

The balance sheet included approximately $1.0 million of current and long-term notes payable. Management separately stated that the company had no material unsecured debt.

The revenue mix mattered more than the headline decline

The central feature of the quarter was the divergence between revenue and gross profit. Revenue was approximately $1.4 million lower than a year earlier, but gross profit was approximately $1.8 million higher. That improvement was sufficient to reduce the operating loss sharply even though total operating expenses remained near the prior-year level.

Higher-margin 340B and medication fulfillment services helped offset lower prescription revenue caused by reimbursement and payer-mix pressure. This means future profitability depends not only on overall sales growth but also on whether NextPlat can continue increasing the contribution from contracted services while preserving the improved healthcare margin.

Management outlook and execution priorities

Management expects the 11 contracted entities signed during the first half to begin contributing revenue during Q3, with a more significant contribution anticipated early in Q4. It also expects positive operating income for the remainder of 2026, supported by higher-margin healthcare revenue and a more efficient expense structure. These expectations were directional rather than a quantified financial forecast.

NextPlat plans to launch a nationwide medication fulfillment website during Q3 2026. After the quarter, it also announced the intended acquisition of a Pensacola-area pharmacy operation described as adding approximately $5.6 million in profitable annual revenue. The transaction had not yet been completed, and management said it was evaluating additional pharmacy acquisitions in Florida.

Risks investors need to watch

• Reimbursement and payer-mix pressure: Lower payer reimbursement rates and payer mix contributed to the decline in total pharmacy prescription revenue. Continued pressure could offset growth in contracted services.
• Contract onboarding: Expected revenue growth depends on converting 11 newly signed entities into active customers. Management indicated that the larger contribution is not expected until early Q4.
• Sensitivity to expenses: The company remained slightly unprofitable on a GAAP basis, and the $0.5 million increase in professional fees shows that relatively modest cost changes can determine whether operating income is positive or negative.
• Working-capital demands: Cash declined by approximately $1.8 million during the first half as receivables and inventory increased. The pace at which those assets convert into cash will affect liquidity.
• Expansion execution: The nationwide website and intended Pensacola acquisition could broaden NextPlat’s healthcare reach, but their contribution depends on successful launch, transaction completion and integration.

Summary

NextPlat’s Q2 2026 results showed a meaningful improvement in earnings quality despite lower year-over-year revenue. Growth in contracted pharmacy services, lower drug acquisition costs and stronger e-commerce sales lifted gross margin and reduced the GAAP net loss to near breakeven. The next test is whether newly signed healthcare customers can generate the expected revenue while the company maintains margin and expense discipline.